Consensus Vertex Pharmaceuticals Incorporated

Stocks

VRTX

US92532F1003

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 09/10/2026 BST			5-day change	1st Jan Change
510.08 ^USD	+1.36%		+1.06%	+12.51%

10-09	Vertex Pharmaceuticals Says Alyftrek Delivers Pancreatic Function Recovery in Some Children	MT
10-09	Vertex Pharmaceuticals Incorporated Presents New Interim Data on Alyftrek in Children Ages 2 to 5 Years At the North American Cystic Fibrosis Conference	CI

Evolution of the Average Target: Vertex Pharmaceuticals Incorporated

Evolution of the Target Price: Vertex Pharmaceuticals Incorporated

Changes in Analyst Recommendations: Vertex Pharmaceuticals Incorporated

0cdfb749e3e168c85cd.MkV_TNd2MRqwbo-JhjWwHcjVDe5NGH8U-5GAuaEytWc.VjAdOLsufXbpDfbWwmz2boW5dLkYSAxSl9LIz8tD4jRtNhx4lBp3WMA76A~c52d45e51dd6cb67d877a109a8acdf77

Analysts' recommendations: Vertex Pharmaceuticals Incorporated

10-08	RBC Lifts Price Target on Vertex Pharmaceuticals to $576 From $570, Keeps Outperform Rating	MT
09-28	UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating	MT
09-23	TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT
09-23	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $640 From $633, Maintains Buy Rating	MT
09-02	Evercore ISI Adjusts Vertex Pharmaceuticals Price Target to $600 From $535, Maintains Outperform Rating	MT
08-12	Vertex Has Multiple Portfolio Catalysts With Favorable Risk-Reward, RBC Says	MT
08-11	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $633 From $610, Maintains Buy Rating	MT
08-11	Daiwa Securities Adjusts Price Target on Vertex Pharmaceuticals to $556 From $555, Maintains Buy Rating	MT
08-05	Rothschild & Co Redburn Adjusts Vertex Pharmaceuticals Price Target to $580 From $570	MT
08-04	Vertex Pharmaceuticals Seen Well Positioned Ahead of Pipeline Catalysts, UBS Says	MT
08-04	Vertex Pharmaceuticals' Solid Q2, Raised Outlook Underscore Core Business Strength, RBC Says	MT
08-04	RBC Capital Adjusts Price Target on Vertex Pharmaceuticals to $570 From $577, Maintains Outperform Rating	MT
08-04	Barclays Adjusts PT on Vertex Pharmaceuticals to $617 From $615, Maintains Overweight Rating	MT
08-04	Goldman Sachs Adjusts PT on Vertex Pharmaceuticals to $653 From $652, Maintains Buy Rating	MT
08-04	Stifel Adjusts Price Target on Vertex Pharmaceuticals to $500 From $466, Maintains Hold Rating	MT
08-04	Cantor Fitzgerald Adjusts PT on Vertex Pharmaceuticals to $595 From $590, Maintains Overweight Rating	MT
08-04	Canaccord Genuity Adjusts PT on Vertex Pharmaceuticals to $442 From $436, Maintains Hold Rating	MT
08-04	TD Cowen Adjusts Price Target on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT
07-21	Morgan Stanley Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $15 From $19	MT
07-20	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $652 From $641, Maintains Buy Rating	MT
07-13	UBS Adjusts Vertex Pharmaceuticals Price Target to $585 From $545, Maintains Buy Rating	MT
07-09	RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $577 From $570	MT
07-08	Jefferies Adjusts Vertex Pharmaceuticals Price Target to $610 From $580	MT
07-07	Vertex Pharmaceuticals' Acquisition of Crinetics Adds Rare-Disease Drugs, UBS Says	MT
07-07	RBC Capital Adjusts Vertex Pharmaceuticals Price Target to $570 From $543, Maintains Outperform Rating	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	VERTEX PHARMACEUTICALS INCORPORATED					+12.06%
	ELI LILLY AND COMPANY					+12.79%
	JOHNSON & JOHNSON					+7.03%
	ABBVIE INC.					+2.22%
	MERCK & CO., INC.					+8.71%
	ROCHE HOLDING AG					+5.14%
	NOVARTIS AG					+4.76%
	ASTRAZENECA PLC					+31.69%
	AMGEN INC.					-4.73%
	GILEAD SCIENCES, INC.					+5.43%
	Average					+8.51%
	Weighted average by Cap.					+8.77%